NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Nanomedicine Innovations Transforming Oncology Drug De ...

AGOURA HILLS, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (OTCQB: OTLC), a biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat cancer patients by leveraging its novel PDAOAI platform and deep knowledge in nanomedicines and the tumor microenvironment, announced today that Sapu Nano will be featuring its investigational intravenous Deciparticle™ everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Bre ...

NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, “Nanomedicine Breakthrough Technology Redefining Drug D ...

Nanobiotix (NBTX) is a clinical-stage nanomedicine company showing exceptional price momentum and technical strength. Shares are trading at new all-time highs. NBTX has surged 440% over the past year. Nanobiotix has a Trend Seeker “Buy” signal and strong technical indicators, but it remains highly volatile. Today’s Featured Stock Valued at $1.3 billion, Nanobiotix (NBTX) is a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer. The company’s proprietary tech ...

公司业务与战略 - 公司是一家临床阶段生物制药公司 专注于开发肿瘤学和免疫疗法产品[4] - 公司使命是通过创新的后期治疗候选药物 解决高度未满足需求的癌症和罕见儿科适应症[4] - 公司通过合资企业进行药物许可和共同开发 目前拥有GMP Bio合资企业45%的股权[4] 技术优势与知识产权 - 公司应用人工智能、纳米医学和创新临床方法重新定义生物技术[3] - 拥有强大的知识产权组合 包括约500项专利申请和75项授权专利[3] - CEO个人拥有150多项专利申请和39项美国授权专利 进一步强化公司技术储备[4] 研发重点领域 - 专注于RNA药物、免疫疗法和靶向治疗领域的进展[2] - 重点攻克胶质母细胞瘤和胰腺癌等最难治疗的致命癌症[2] - 同时关注罕见儿科疾病治疗领域 致力于减少对年轻患者的伤害[2] 行业地位与认可 - 公司因在重大未满足医疗需求领域的突出表现获得专业媒体报道[1][3] - 通过NetworkNewsWire金融新闻平台向投资界传播公司进展[1][5] - 报道强调公司在癌症研究领域的突破为全球患者带来新希望[2]